The U.S. large molecule drug substance CDMO market continues to reinforce its strategic position within the global biopharmaceutical value chain, with the market valued at USD 12.34 billion in 2024 and expanding at a projected CAGR of 7.5% from 2025 to 2034. This growth trajectory reflects the rising reliance of biopharma developers on external partners for biologics development,...
Spanish 
English
Arabic
French
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek